MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients

MAIA Biotechnology, Inc., announced positive efficacy data for third-line treatment in its Phase II THIO-101 clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor cemiplimab in advanced non-small cell lung cancer.